Business Wire | Oct 27, 2020 04:01PM EDT

Personalis to Participate in Upcoming Investor Conferences

Oct. 27, 2020

MENLO PARK, Calif.--(BUSINESS WIRE)--Oct. 27, 2020--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that company management will participate in the following upcoming investor conferences.

* 29th Annual Credit Suisse Virtual Healthcare Conference Presenting on Tuesday, November 10, 2020 at 4:15 p.m. Eastern Time

* Oppenheimer Fall MedTech Summit Participating on Thursday, November 12, 2020

About Personalis, Inc.

Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient's cancer and immune response. The Personalis(r) ImmunoID NeXT Platform(r) is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue or blood sample. Personalis also provides genomic information to the VA Million Veterans Program as part of their goal to sequence over two million veteran genomes. The Personalis Clinical Laboratory is GxP aligned as well as CLIA'88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc).

View source version on businesswire.com: https://www.businesswire.com/news/home/20201027005148/en/

CONTACT: Investor Relations Contact: Caroline Corner investors@personalis.com 415-202-5678

CONTACT: Media Contact: Jennifer Havlek pr@personalis.com www.personalis.com 650-752-1300